Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma

Bookmark and Share
Published: 1 Jun 2020
Views: 157
Rating:
Save
Dr Shaji Kumar - Mayo Clinic, Rochester, USA

Dr Shaji Kumar speaks to ecancer about updated results from the BELLINI trial that were presented at the ASCO 2020 Virtual Meeting.

The phase III study was of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.

Dr Kumar explains that although the addition of venetoclax to bortezomib and dexamethasone improved progression-free survival, it resulted in increased mortality.